ALK+ Advanced NSCLC
Conditions
Keywords
Drug Therapy
Brief summary
Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this study, participants will be people with non-small-cell lung cancer (NSCLC for short). The main aim of the study is to learn if brigatinib stops the tumors from growing, or if the tumors have shrunk or disappeared, compared to a medicine called alectinib. At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 treatments by chance: * Brigatinib tablets * Alectinib capsules All participants will take brigatinib or alectinib at about the same time every day. They will continue with treatment throughout the study unless their cancer gets worse, they have side effects from the treatment, they leave the study for certain reasons, or the study is stopped. After stopping treatment, participants will visit the study clinic for a check-up 30 days later.
Detailed description
The drug being tested in this study is called brigatinib. Brigatinib has been demonstrated to benefit people with anaplastic lymphoma kinase-positive (ALK+) NSCLC. The comparator drug is called alectinib. Alectinib has been demonstrated to benefit people with ALK+ NSCLC. Both drugs belong to a class of drugs called anaplastic lymphoma kinase (ALK) inhibitors. Both drugs are taken by mouth. Both drugs are approved by the United States Food and Drug Administration (US FDA). The study will enroll approximately 246 participants. Participants will be randomly assigned (by chance, like flipping a coin) in 1:1 ratio to one of the two treatment groups: * Brigatinib * Alectinib All participants will be asked to take brigatinib or alectinib at the same time each day throughout the study. For each participant eligible to continue in the study and to facilitate the remaining participants from Brigatinib-2002 (NCT03535740) to have continued treatment access, the study extension phase may be initiated for participants to continue receiving their randomized study treatment (i.e., brigatinib or alectinib) until they meet at least one of the treatment discontinuation criteria. This multi-center trial will be conducted in the United States, Argentina, Austria, Canada, Chile, China, Croatia, France, Germany, Greece, Hong Kong, Italy, Mexico, Romania, Russia, South Korea, Spain, Sweden, Taiwan, and Thailand. The overall time to participate in this study is 5 years. Participants will make multiple visits to the clinic, and 30 days after last dose of study drug for a follow-up assessment.
Interventions
DRUGBrigatinib
Brigatinib Tablets.
DRUGAlectinib
Alectinib Capsules.
Sponsors
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 2. Have histologically or cytologically confirmed stage IIIB (locally advanced or recurrent) or stage IV NSCLC. 3. Must meet one of the following criteria: * Have documentation of ALK rearrangement by a positive result from the Vysis ALK Break-Apart fluorescence in situ hybridization (FISH) Probe Kit or the Ventana ALK (D5F3) CDx Assay or Foundation Medicine's FoundationOne CDx. * Have documented ALK rearrangement by a different test and be able to provide tumor sample to the central laboratory. (Note: central laboratory ALK rearrangement testing results are not required to be obtained before randomization). 4. Had PD while on crizotinib, as assessed by the investigator or treating physician except for participants previously participating in the Brigatinib-2002 study (Note: crizotinib does not need to be the last therapy a participant received. The participant may have received chemotherapy as his/her last therapy). 5. Treatment with crizotinib for at least 4 weeks before progression except for participants previously participating in the Brigatinib-2002 study. 6. Have had no other ALK inhibitor other than crizotinib except for participants previously participating in the Brigatinib-2002 study. 7. Have had no more than 2 prior regimens of systemic anticancer therapy (other than crizotinib) in the locally advanced or metastatic setting. Note: a systemic anticancer therapy regimen will be counted if it is administered for at least 1 complete cycle. A new anticancer agent used as maintenance therapy will be counted as a new regimen. Neoadjuvant or adjuvant systemic anticancer therapy will be counted as a prior regimen if disease progression/recurrence occurred within 12 months upon completion of this neoadjuvant or adjuvant therapy. (Systemic therapy followed by maintenance therapy will be considered as one regimen if the maintenance therapy consists of a drug or drugs that were used in the regimen that immediately preceded maintenance). 8. Have at least 1 measurable (that is, target) lesion per RECIST v1.1. 9. Have recovered from toxicities related to prior anticancer therapy to national cancer institute common terminology criteria for adverse events (NCI CTCAE) version 4.03 grade less than or equal to (\<=)1. (Note: treatment-related alopecia or peripheral neuropathy that are grade greater than (\>) 1 are allowed, if deemed irreversible). 10. Have adequate organ function, at the time of initial screening, except for participants previously participating in the Brigatinib-2002 study as determined by: * Total bilirubin \<=1.5 times the upper limit of normal (ULN). * Estimated glomerular filtration rate greater than equal to (\>=) 30 milliliter per minute (mL/min)/1.73 square meter \[m\^2\], using the modification of diet in renal disease equation. * Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) \<=2.5\*ULN; \<=5\*ULN is acceptable if liver metastases are present. * Serum lipase \<=1.5\*ULN. * Platelet count \>=75\*10\^9 per liter \[/L\]. * Hemoglobin \>=9 gram per deciliter (g/dL). * Absolute neutrophil count \>=1.5\*10\^9 / L. 11. Suitable venous access for study-required blood sampling (that is, including pharmacokinetic \[PK\] and laboratory safety tests).
Exclusion criteria
1. Had participated in the control (crizotinib) arm of Study AP26113-13-301 (ALTA 1L) \[NCT02737501\]. 2. Had received crizotinib within 7 days before randomization. 3. Have a history or presence at baseline of pulmonary interstitial disease, drug related pneumonitis, or radiation pneumonitis. 4. Have uncontrolled hypertension. Participants with hypertension should be under treatment for control of blood pressure upon study entry. 5. Had received systemic treatment with strong cytochrome P-450 (CYP) 3A inhibitors, moderate CYP3A inhibitors, strong CYP3A inducers, or moderate CYP3A inducers within 14 days before randomization. 6. Treatment with any investigational systemic anticancer agents within 14 days or 5 half-lives, whichever is longer, before randomization. 7. Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated nonmelanoma skin cancer or cervical cancer in situ; definitively treated nonmetastatic prostate cancer; or participants with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy. 8. Had received chemotherapy or radiation therapy within 14 days before randomization except for stereotactic radiosurgery (SRS) or stereotactic body radiation therapy. 9. Had received antineoplastic monoclonal antibodies within 30 days of randomization. 10. Had major surgery within 30 days of randomization. Minor surgical procedures, such as catheter placement or minimally invasive biopsies, are allowed. 11. Have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening (participants with asymptomatic brain metastases or participants who have stable symptoms and did not require an increased dose of corticosteroids to control symptoms within 7 days before randomization will be enrolled). Note: If a participant has worsening neurological symptoms or signs due to CNS metastasis, the participant needs to complete local therapy and be neurologically stable (with no requirement for an increasing dose of corticosteroids or use of anticonvulsants) for 7 days before randomization. 12. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Participants with leptomeningeal disease and without cord compression are allowed. 13. Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to the following: * Myocardial infarction within 6 months before randomization. * Unstable angina within 6 months before randomization. * New York Heart Association Class III or IV heart failure within 6 months before randomization. * History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician. * Any history of clinically significant ventricular arrhythmia. 14. Had cerebrovascular accident or transient ischemic attack within 6 months before first dose of study drug. 15. Have malabsorption syndrome or other gastrointestinal illness or condition that could affect oral absorption of the study drug. 16. Have an ongoing or active infection, including but not limited to, the requirement for intravenous antibiotics. 17. Have a known history of human immunodeficiency virus (HIV) infection. Testing is not required in the absence of history. 18. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection. Testing is not required in the absence of history. 19. Any serious medical condition or psychiatric illness that could, in the investigator's opinion, potentially compromise participant safety or interfere with the completion of treatment according to this protocol. 20. Have a known or suspected hypersensitivity to brigatinib or alectinib or their excipients. 21. Life-threatening illness unrelated to cancer. 22. Female participants who are lactating and breastfeeding. 23. Admission or evidence of illicit drug use, drug abuse, or alcohol abuse.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 | Up to 33.8 months | PFS is defined as the time interval from the date of randomization until the first date at which disease progression is objectively documented via RECIST v1.1 by BIRC, or death due to any cause, whichever occurs first, in the full analysis set. PFS was censored for participants without documented disease progression or death at the last valid tumor response assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS as Assessed by Investigator Per RECIST v1.1 | Up to 33.8 months | PFS is defined as the time interval from the date of randomization until the first date at which disease progression is objectively documented via RECIST v1.1 by investigator, or death due to any cause, whichever occurs first, in the full analysis set. PFS was censored for participants without documented disease progression or death at the last valid tumor response assessment. |
| Objective Response Rate (ORR) as Assessed by BIRC and Investigator Per RECIST v1.1 | Up to 33.8 months | ORR is defined as the percentage of the participants who are confirmed to have achieved complete response (CR) or partial response (PR), using RECIST v1.1 after the initiation of study treatment. Percentages were rounded off to the nearest single decimal place. |
| Duration of Response (DOR) as Assessed by BIRC and Investigator Per RECIST v1.1 | Up to 33.8 months | DOR is defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that the progressive disease (PD) is objectively documented or death, as assessed by the investigator and BIRC, using RECIST v1.1. Participants who did not progress or died, were censored at the last tumor assessment date prior to receiving subsequent anticancer therapy. |
| Time to Response as Assessed by Investigator and BIRC Per RECIST v1.1 | Up to 33.8 months | Time to response is defined as the time interval from randomization until the initial observation of CR or PR, as assessed by the investigator and BIRC, using RECIST v1.1. Time to response will be summarized using descriptive statistics in participants with confirmed objective response. |
| Overall Survival (OS) | Up to 64 months | OS is defined as the time interval from the date of randomization until death due to any cause in the full analysis set. OS was censored on the date of last contact for those participants who are alive. |
| Intracranial Duration of Response (iDOR) as Assessed by the BIRC Per Modified RECIST v1.1 | Up to 33.8 months | iDOR, as assessed by the BIRC per modified RECIST v1.1, is defined as the time interval from the time that the measurement criteria are first met for CR or PR in the CNS (whichever is first recorded) until the first date that the PD in the CNS is objectively documented or death. Participants who did not progress or died, were censored at the last iCNS tumor assessment date prior to receiving subsequent anticancer therapy. |
| Cumulative Incidence of Intracranial Disease Progression (iPD) as Assessed by BIRC Per Modified RECIST v1.1 | 6, 12, 18 and 24 months | Time to iPD as assessed by the BIRC,is defined as time interval from date of randomization until first date at which iPD is objectively documented via a modification of RECIST v1.1 without prior systemic progression (PD) or death. Time to iPD was analyzed within a competing risk framework (with systemic progression and death as the competing risks) by estimating the cumulative incidence function (CIF) within each arm. The CIF is a function of time, and indicates the probability of an event (e.g. iPD without prior PD or death) occurring by the specified time. The estimated CIFs were analyzed using Grey's Test and the estimated probability of CIFs is reported at pre-specified landmark times (6, 12, 18 and 24 months). |
| Health-Related Quality of Life (HRQOL) From European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 v3.0) Score | Up to 33.8 months | EORTC QLQ-C30 incorporates 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC QLQ-C30 contains 28 questions (4-point scale where 1=Not at all \[best\] to 4=Very Much \[worst\]) and 2 questions (7-point scale where 1=Very poor \[worst\] to 7= Excellent \[best\]). Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status scale, higher scores represent better quality of life (QOL); for the symptom scales, lower scores represent better QOL. |
| HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | Up to 33.8 months | HRQOL scores were assessed with European Organization for Research and Treatment (EORTC), its lung cancer module QLQ-LC13. QLQ-LC13 contains 13 questions assessing lung cancer-associated symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and use of pain medication. Subscales were scored on a range of 0 to 100. Higher symptom score = greater degree of symptom severity. |
| Confirmed Intracranial Objective Response Rate (iORR) as Assessed by BIRC Per Modified RECIST v1.1 | Up to 33.8 months | Confirmed iORR, as assessed by the BIRC, is defined as the percentage of the participants who have achieved CR or PR in the central nervous system (CNS) per a modification RECIST v1.1 after the initiation of study treatment in participants with CNS metastases at baseline. Percentages were rounded off to the nearest single decimal place. |
Countries
Argentina, Austria, Canada, Chile, China, Croatia, France, Germany, Greece, Hong Kong, Italy, Mexico, Romania, Russia, South Korea, Spain, Sweden, Taiwan, Thailand, United States
Participant flow
Recruitment details
Participants took part in the study at various investigative sites globally from 19 April 2019 to 18 September 2024.
Pre-assignment details
Participants with anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC) who had progressed on crizotinib were administered either brigatinib or alectinib in this study.
Participants by arm
| Arm | Count |
|---|---|
| Brigatinib Participants were administered brigatinib 90 mg, tablets, orally, QD for 7 days, followed by brigatinib 180 mg, tablets, orally, QD until objective disease progression per RECIST v1.1, as assessed by the investigator, or intolerable toxicity, or up to 33.8 months. | 125 |
| Alectinib Participants were administered alectinib 600 mg, capsules, orally, BID until objective disease progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicity, or up to 33.8 months. | 123 |
| Total | 248 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 37 | 24 |
| Overall Study | Lost to Follow-up | 2 | 3 |
| Overall Study | Missing | 0 | 6 |
| Overall Study | Protocol Violation | 1 | 0 |
| Overall Study | Reason Not Specified | 14 | 13 |
| Overall Study | Site terminated by Sponsor | 64 | 65 |
| Overall Study | Withdrawal by Subject | 4 | 6 |
Baseline characteristics
| Characteristic | Total | Brigatinib | Alectinib |
|---|---|---|---|
| Age, Continuous | 53 years STANDARD_DEVIATION 12.84 | 53.0 years STANDARD_DEVIATION 12.17 | 52.9 years STANDARD_DEVIATION 13.53 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 21 Participants | 7 Participants | 14 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 222 Participants | 116 Participants | 106 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 5 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 140 Participants | 74 Participants | 66 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 4 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) White | 102 Participants | 50 Participants | 52 Participants |
| Sex: Female, Male Female | 135 Participants | 67 Participants | 68 Participants |
| Sex: Female, Male Male | 113 Participants | 58 Participants | 55 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 37 / 125 | 25 / 123 |
| other Total, other adverse events | 122 / 125 | 118 / 122 |
| serious Total, serious adverse events | 38 / 125 | 24 / 122 |
Outcome results
Primary
Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1
PFS is defined as the time interval from the date of randomization until the first date at which disease progression is objectively documented via RECIST v1.1 by BIRC, or death due to any cause, whichever occurs first, in the full analysis set. PFS was censored for participants without documented disease progression or death at the last valid tumor response assessment.
Time frame: Up to 33.8 months
Population: FAS included all participants randomized to each regimen regardless of whether they were ALK+ by an FDA approved test (Vysis ALK Break Apart FISH Probe Kit, Ventana ALK (D5F3) CDx Assay, Foundation Medicine's FoundationOne CDx) or a local test other than FISH and immunohistochemistry, or whether they received study drug or adhered to the assigned dose.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brigatinib | Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 | 19.253 months |
| Alectinib | Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 | 19.187 months |
p-value: =0.867295% CI: [0.658, 1.424]2-sided Stratified Log-rank Test
Secondary
Confirmed Intracranial Objective Response Rate (iORR) as Assessed by BIRC Per Modified RECIST v1.1
Confirmed iORR, as assessed by the BIRC, is defined as the percentage of the participants who have achieved CR or PR in the central nervous system (CNS) per a modification RECIST v1.1 after the initiation of study treatment in participants with CNS metastases at baseline. Percentages were rounded off to the nearest single decimal place.
Time frame: Up to 33.8 months
Population: Measurable iCNS disease population included all participants in the full analysis population determined by the BIRC to have had at least 1 measurable iCNS tumor lesion.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Brigatinib | Confirmed Intracranial Objective Response Rate (iORR) as Assessed by BIRC Per Modified RECIST v1.1 | 73.3 percentage of participants |
| Alectinib | Confirmed Intracranial Objective Response Rate (iORR) as Assessed by BIRC Per Modified RECIST v1.1 | 67.7 percentage of participants |
p-value: =0.624695% CI: [0.44, 3.84]Cochran-Mantel-Haenszel
Secondary
Cumulative Incidence of Intracranial Disease Progression (iPD) as Assessed by BIRC Per Modified RECIST v1.1
Time to iPD as assessed by the BIRC,is defined as time interval from date of randomization until first date at which iPD is objectively documented via a modification of RECIST v1.1 without prior systemic progression (PD) or death. Time to iPD was analyzed within a competing risk framework (with systemic progression and death as the competing risks) by estimating the cumulative incidence function (CIF) within each arm. The CIF is a function of time, and indicates the probability of an event (e.g. iPD without prior PD or death) occurring by the specified time. The estimated CIFs were analyzed using Grey's Test and the estimated probability of CIFs is reported at pre-specified landmark times (6, 12, 18 and 24 months).
Time frame: 6, 12, 18 and 24 months
Population: FAS included all participants randomized to each regimen regardless of whether they are ALK+ by an FDA approved test (Vysis ALK Break Apart FISH Probe Kit, Ventana ALK (D5F3) CDx Assay, Foundation Medicine's FoundationOne CDx) or a local test other than FISH and immunohistochemistry, or whether they receive study drug or adhere to the assigned dose.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Brigatinib | Cumulative Incidence of Intracranial Disease Progression (iPD) as Assessed by BIRC Per Modified RECIST v1.1 | 6 months | 0.115 probability |
| Brigatinib | Cumulative Incidence of Intracranial Disease Progression (iPD) as Assessed by BIRC Per Modified RECIST v1.1 | 12 months | 0.218 probability |
| Brigatinib | Cumulative Incidence of Intracranial Disease Progression (iPD) as Assessed by BIRC Per Modified RECIST v1.1 | 18 months | 0.305 probability |
| Brigatinib | Cumulative Incidence of Intracranial Disease Progression (iPD) as Assessed by BIRC Per Modified RECIST v1.1 | 24 months | 0.388 probability |
| Alectinib | Cumulative Incidence of Intracranial Disease Progression (iPD) as Assessed by BIRC Per Modified RECIST v1.1 | 24 months | 0.248 probability |
| Alectinib | Cumulative Incidence of Intracranial Disease Progression (iPD) as Assessed by BIRC Per Modified RECIST v1.1 | 6 months | 0.076 probability |
| Alectinib | Cumulative Incidence of Intracranial Disease Progression (iPD) as Assessed by BIRC Per Modified RECIST v1.1 | 18 months | 0.209 probability |
| Alectinib | Cumulative Incidence of Intracranial Disease Progression (iPD) as Assessed by BIRC Per Modified RECIST v1.1 | 12 months | 0.171 probability |
p-value: =0.0778Gray's Test
Secondary
Duration of Response (DOR) as Assessed by BIRC and Investigator Per RECIST v1.1
DOR is defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that the progressive disease (PD) is objectively documented or death, as assessed by the investigator and BIRC, using RECIST v1.1. Participants who did not progress or died, were censored at the last tumor assessment date prior to receiving subsequent anticancer therapy.
Time frame: Up to 33.8 months
Population: FAS=all participants randomized to each regimen regardless of whether they are ALK+ by an FDA approved test (Vysis ALK Break Apart FISH Probe Kit, Ventana ALK (D5F3) CDx Assay, Foundation Medicine's FoundationOne CDx) or a local test other than FISH and immunohistochemistry, or whether they receive study drug or adhere to the assigned dose. N=number of participants with data available for analysis. n=number of participants with data available for analysis at specified categories.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Brigatinib | Duration of Response (DOR) as Assessed by BIRC and Investigator Per RECIST v1.1 | BIRC Assessed | 17.544 months |
| Brigatinib | Duration of Response (DOR) as Assessed by BIRC and Investigator Per RECIST v1.1 | Investigator Assessed | 17.511 months |
| Alectinib | Duration of Response (DOR) as Assessed by BIRC and Investigator Per RECIST v1.1 | BIRC Assessed | 20.205 months |
| Alectinib | Duration of Response (DOR) as Assessed by BIRC and Investigator Per RECIST v1.1 | Investigator Assessed | 19.614 months |
Secondary
Health-Related Quality of Life (HRQOL) From European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 v3.0) Score
EORTC QLQ-C30 incorporates 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC QLQ-C30 contains 28 questions (4-point scale where 1=Not at all \[best\] to 4=Very Much \[worst\]) and 2 questions (7-point scale where 1=Very poor \[worst\] to 7= Excellent \[best\]). Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status scale, higher scores represent better quality of life (QOL); for the symptom scales, lower scores represent better QOL.
Time frame: Up to 33.8 months
Population: The patient-reported outcome (PRO) analysis set included all participants with baseline and at least 1 post-baseline PRO measurement in the full analysis set. Overall number analyzed is the number of participants with data available for analysis of this outcome measure at end of treatment visit.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brigatinib | Health-Related Quality of Life (HRQOL) From European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 v3.0) Score | 86.15 score on a scale |
| Alectinib | Health-Related Quality of Life (HRQOL) From European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 v3.0) Score | 84.74 score on a scale |
Secondary
HRQOL From EORTC QLQ- Lung Cancer (LC) 13
HRQOL scores were assessed with European Organization for Research and Treatment (EORTC), its lung cancer module QLQ-LC13. QLQ-LC13 contains 13 questions assessing lung cancer-associated symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and use of pain medication. Subscales were scored on a range of 0 to 100. Higher symptom score = greater degree of symptom severity.
Time frame: Up to 33.8 months
Population: The PRO analysis set included all participants with baseline and at least 1 post-baseline PRO measurement in the full analysis set. Overall number analyzed is the number of participants with data available for analysis of this outcome measure at end of treatment visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Brigatinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Dyspnoea | 22.22 score on a scale |
| Brigatinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Coughing | 33.33 score on a scale |
| Brigatinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Haemoptysis | 0.00 score on a scale |
| Brigatinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Sore mouth | 0.00 score on a scale |
| Brigatinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Dysphagia | 0.00 score on a scale |
| Brigatinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Peripheral neuropathy | 0.00 score on a scale |
| Brigatinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Alopecia | 0.00 score on a scale |
| Brigatinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Pain in chest | 0.00 score on a scale |
| Brigatinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Pain in arm or shoulder | 0.00 score on a scale |
| Brigatinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Pain in other parts | 0.00 score on a scale |
| Alectinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Pain in chest | 0.00 score on a scale |
| Alectinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Dyspnoea | 11.11 score on a scale |
| Alectinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Peripheral neuropathy | 0.00 score on a scale |
| Alectinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Coughing | 33.33 score on a scale |
| Alectinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Pain in other parts | 0.00 score on a scale |
| Alectinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Haemoptysis | 0.00 score on a scale |
| Alectinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Alopecia | 0.00 score on a scale |
| Alectinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Sore mouth | 0.00 score on a scale |
| Alectinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Pain in arm or shoulder | 0.00 score on a scale |
| Alectinib | HRQOL From EORTC QLQ- Lung Cancer (LC) 13 | End of Treatment: Dysphagia | 0.00 score on a scale |
Secondary
Intracranial Duration of Response (iDOR) as Assessed by the BIRC Per Modified RECIST v1.1
iDOR, as assessed by the BIRC per modified RECIST v1.1, is defined as the time interval from the time that the measurement criteria are first met for CR or PR in the CNS (whichever is first recorded) until the first date that the PD in the CNS is objectively documented or death. Participants who did not progress or died, were censored at the last iCNS tumor assessment date prior to receiving subsequent anticancer therapy.
Time frame: Up to 33.8 months
Population: Measurable iCNS disease population included all participants in the full analysis population determined by the BIRC to have had at least 1 measurable iCNS tumor lesion. Overall number analyzed is the number of participants with data available for analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brigatinib | Intracranial Duration of Response (iDOR) as Assessed by the BIRC Per Modified RECIST v1.1 | 17.413 months |
| Alectinib | Intracranial Duration of Response (iDOR) as Assessed by the BIRC Per Modified RECIST v1.1 | NA months |
Secondary
Objective Response Rate (ORR) as Assessed by BIRC and Investigator Per RECIST v1.1
ORR is defined as the percentage of the participants who are confirmed to have achieved complete response (CR) or partial response (PR), using RECIST v1.1 after the initiation of study treatment. Percentages were rounded off to the nearest single decimal place.
Time frame: Up to 33.8 months
Population: FAS included all participants randomized to each regimen regardless of whether they are ALK+ by an FDA approved test (Vysis ALK Break Apart FISH Probe Kit, Ventana ALK (D5F3) CDx Assay, Foundation Medicine's FoundationOne CDx) or a local test other than FISH and immunohistochemistry, or whether they receive study drug or adhere to the assigned dose.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Brigatinib | Objective Response Rate (ORR) as Assessed by BIRC and Investigator Per RECIST v1.1 | BIRC Assessed | 52.0 percentage of participants |
| Brigatinib | Objective Response Rate (ORR) as Assessed by BIRC and Investigator Per RECIST v1.1 | Investigator Assessed | 40.8 percentage of participants |
| Alectinib | Objective Response Rate (ORR) as Assessed by BIRC and Investigator Per RECIST v1.1 | BIRC Assessed | 61.0 percentage of participants |
| Alectinib | Objective Response Rate (ORR) as Assessed by BIRC and Investigator Per RECIST v1.1 | Investigator Assessed | 56.1 percentage of participants |
Comparison: BIRC Assessedp-value: =0.155595% CI: [0.42, 1.15]Cochran-Mantel-Haenszel
Comparison: Investigator Assessedp-value: =0.016995% CI: [0.33, 0.9]Cochran-Mantel-Haenszel
Secondary
Overall Survival (OS)
OS is defined as the time interval from the date of randomization until death due to any cause in the full analysis set. OS was censored on the date of last contact for those participants who are alive.
Time frame: Up to 64 months
Population: FAS included all participants randomized to each regimen regardless of whether they are ALK+ by an FDA approved test (Vysis ALK Break Apart FISH Probe Kit, Ventana ALK (D5F3) CDx Assay, Foundation Medicine's FoundationOne CDx) or a local test other than FISH and immunohistochemistry, or whether they receive study drug or adhere to the assigned dose.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brigatinib | Overall Survival (OS) | NA months |
| Alectinib | Overall Survival (OS) | NA months |
p-value: =0.071395% CI: [0.956, 2.652]Log Rank
Secondary
PFS as Assessed by Investigator Per RECIST v1.1
PFS is defined as the time interval from the date of randomization until the first date at which disease progression is objectively documented via RECIST v1.1 by investigator, or death due to any cause, whichever occurs first, in the full analysis set. PFS was censored for participants without documented disease progression or death at the last valid tumor response assessment.
Time frame: Up to 33.8 months
Population: FAS included all participants randomized to each regimen regardless of whether they are ALK+ by an FDA approved test (Vysis ALK Break Apart FISH Probe Kit, Ventana ALK (D5F3) CDx Assay, Foundation Medicine's FoundationOne CDx) or a local test other than FISH and immunohistochemistry, or whether they receive study drug or adhere to the assigned dose.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brigatinib | PFS as Assessed by Investigator Per RECIST v1.1 | 16.789 months |
| Alectinib | PFS as Assessed by Investigator Per RECIST v1.1 | 16.591 months |
p-value: =0.250195% CI: [0.862, 1.761]Log Rank
Secondary
Time to Response as Assessed by Investigator and BIRC Per RECIST v1.1
Time to response is defined as the time interval from randomization until the initial observation of CR or PR, as assessed by the investigator and BIRC, using RECIST v1.1. Time to response will be summarized using descriptive statistics in participants with confirmed objective response.
Time frame: Up to 33.8 months
Population: FAS=all participants randomized to each regimen regardless of whether they are ALK+ by an FDA approved test (Vysis ALK Break Apart FISH Probe Kit, Ventana ALK (D5F3) CDx Assay, Foundation Medicine's FoundationOne CDx) or a local test other than FISH and immunohistochemistry, or whether they receive study drug or adhere to the assigned dose. N=number of participants with data available for analysis. n=number of participants with data available for analysis at specified categories.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Brigatinib | Time to Response as Assessed by Investigator and BIRC Per RECIST v1.1 | BIRC Assessed | 1.873 months |
| Brigatinib | Time to Response as Assessed by Investigator and BIRC Per RECIST v1.1 | Investigator Assessed | 1.873 months |
| Alectinib | Time to Response as Assessed by Investigator and BIRC Per RECIST v1.1 | BIRC Assessed | 1.840 months |
| Alectinib | Time to Response as Assessed by Investigator and BIRC Per RECIST v1.1 | Investigator Assessed | 1.873 months |